Product

Symtuza

Name

Symtuza

INN Name

Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide

FDA Approved

Yes

3 clinical trials

1 organization

4 indications

1 document

Indication

Indication

Indication

Indication

Clinical trial

Effect of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Bictegravir/Emtricitabine/Tenofovir Alafenamide on the Circulatory microRNA Profile in Treatment naïve HIV Patients, and Its Correlation With Change in Body Weight

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Status: Completed, Estimated PCD: 2023-07-30

Clinical trial

An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Document

DailyMed Label: Symtuza

Organization

Janssen Products LP